IMV Inc. (NASDAQ: IMV) (TSX: IMV) Starts Presentation at The LD 500
IMV Inc. (NASDAQ: IMV) (TSX: IMV) is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T-cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is…







